126 related articles for article (PubMed ID: 14551142)
1. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.
Chevallier N; Corcoran CM; Lennon C; Hyjek E; Chadburn A; Bardwell VJ; Licht JD; Melnick A
Blood; 2004 Feb; 103(4):1454-63. PubMed ID: 14551142
[TBL] [Abstract][Full Text] [Related]
2. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.
Melnick AM; Westendorf JJ; Polinger A; Carlile GW; Arai S; Ball HJ; Lutterbach B; Hiebert SW; Licht JD
Mol Cell Biol; 2000 Mar; 20(6):2075-86. PubMed ID: 10688654
[TBL] [Abstract][Full Text] [Related]
3. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
4. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
[TBL] [Abstract][Full Text] [Related]
5. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
Lutterbach B; Sun D; Schuetz J; Hiebert SW
Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
[TBL] [Abstract][Full Text] [Related]
6. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
[TBL] [Abstract][Full Text] [Related]
7. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
[TBL] [Abstract][Full Text] [Related]
8. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
9. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
10. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
[TBL] [Abstract][Full Text] [Related]
11. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
12. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
13. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.
Wong CW; Privalsky ML
J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306
[TBL] [Abstract][Full Text] [Related]
14. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.
Era T; Asou N; Kunisada T; Yamasaki H; Asou H; Kamada N; Nishikawa S; Yamaguchi K; Takatsuki K
Genes Chromosomes Cancer; 1995 May; 13(1):25-33. PubMed ID: 7541640
[TBL] [Abstract][Full Text] [Related]
15. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.
Dhordain P; Lin RJ; Quief S; Lantoine D; Kerckaert JP; Evans RM; Albagli O
Nucleic Acids Res; 1998 Oct; 26(20):4645-51. PubMed ID: 9753732
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
17. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO.
Lausen J; Cho S; Liu S; Werner MH
J Biol Chem; 2004 Nov; 279(47):49281-8. PubMed ID: 15377655
[TBL] [Abstract][Full Text] [Related]
18. Multiple regions of ETO cooperate in transcriptional repression.
Hildebrand D; Tiefenbach J; Heinzel T; Grez M; Maurer AB
J Biol Chem; 2001 Mar; 276(13):9889-95. PubMed ID: 11150306
[TBL] [Abstract][Full Text] [Related]
19. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
20. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]